Activated protein C in patients with septic shock: A consecutive case series

International Journal of Clinical Pharmacy

Volumn 34, Issue 1, 2012, Pages 23-26

  Wagner, Jens A ^a   Langenfeld, Heiner ^a   Klett, Luise ^a   Störk, Stefan ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

APACHE score; Drotrecogin alfa; Mortality; Organ failure; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; PROTEIN C;

ACUTE KIDNEY FAILURE; ADULT; AGED; APACHE; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CASE STUDY; DRUG EFFECT; FEMALE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SEPTIC SHOCK; HOSPITALIZATION; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; APACHE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN C; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860806334     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-011-9588-9     Document Type: Article

References (11)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-10.
2. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med. 2003;168(2):165-72.
3. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709.
4. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med. 2005;33(10):2266-77.
5. AbrahamE,Laterre PF, GargR,LevyH,TalwarD,Trzaskoma BL, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353(13):1332-41.
6. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36(1):296-327.
7. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest. 1992;101(6): 1481-3.
8. Brierley J, Carcillo JA, Choong K, Cornell T, Decaen A, Deymann A, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med. 2009;37(2):666-88.
9. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. An evaluation of outcome from intensive care in major medical centers. Ann Intern Med. 1986;104(3):410-8.
10. Holler E, Kolb HJ, Greinix H, Perrotin D, Campilho F, Aversa F, et al. Bleeding events and mortality in SCT patients: a retrospective study of hematopoietic SCT patients with organ dysfunctions due to severe sepsis or GVHD. Bone Marrow Transplant. 2009;43(6):491-7.
11. Levy M, Levi M, Williams MD, Antonelli M, Wang D, Mignini MA. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis. Intensive Care Med. 2009;35(7):1196-203.